Literature DB >> 11444822

Low asialoglycoprotein receptor expression as markers for highly proliferative potential hepatocytes.

H Ise1, N Sugihara, N Negishi, T Nikaido, T Akaike.   

Abstract

Development of a reliable method to isolate highly proliferative potential hepatocytes will provide insight into the molecular mechanisms of liver regeneration, as well as proving crucial for the development of a biohybrid artificial liver. The aim of this study is to isolate highly proliferative, e.g., progenitor-like, hepatocytes. To this end, we fractionated hepatocytes expressing low and high levels of the asialoglycoprotein receptor (ASGP-R) based on the difference in their adhesion to poly[N-p-vinylbenzyl-O-beta-d-galactopyranosyl-(1-->4)-d-gluconamide] (PVLA), and examined the proliferative activity and gene expression of these fractionated hepatocytes. The results showed that approximately 0.5 to 1% of the total number of hepatocytes, which showed low adhesion to PVLA, expressed low levels of the ASGP-R, while the rest of hepatocyte population with high adhesion to PVLA expressed high levels of the ASGP-R. Interestingly hepatocytes with low ASGP-R expression levels had much higher DNA synthesizing activity (i.e., are much more proliferative) than those with high ASGP-R expression levels. Moreover, hepatocytes with low ASGP-R expression levels expressed higher levels of epidermal growth factor receptor (EGF-R), CD29 (beta1 integrin) and CD49f (alpha6 integrin) and lower levels of glutamine synthetase than those with high ASGP-R expression. These findings suggested that hepatocytes with low adhesion to PVLA due to their low ASGP-R expression could be potential candidates for progenitor-like hepatocytes due to their high proliferative capacity; hence, the low expression of the ASGP-R could be a unique marker for progenitor hepatocytes. The isolation of hepatocytes with different functional phenotypes using PVLA may provide a new research tool for a better understanding of the biology of hepatocytes and the mechanisms regulating their proliferation and differentiation in health and disease. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11444822     DOI: 10.1006/bbrc.2001.5139

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  A population of c-Kit(low)(CD45/TER119)- hepatic cell progenitors of 11-day postcoitus mouse embryo liver reconstitutes cell-depleted liver organoids.

Authors:  Susana Minguet; Isabel Cortegano; Pilar Gonzalo; José-Alberto Martínez-Marin; Belén de Andrés; Clara Salas; David Melero; Maria-Luisa Gaspar; Miguel A R Marcos
Journal:  J Clin Invest       Date:  2003-10       Impact factor: 14.808

2.  Establishment of a human neonatal hepatocyte cell line.

Authors:  Yvonne Reid; Jaya P Gaddipati; Deepmala Yadav; Judy Kantor
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-30       Impact factor: 2.416

3.  Matrix metalloproteinase-2 cleavage of the β1 integrin ectodomain facilitates colon cancer cell motility.

Authors:  Jakub Kryczka; Marta Stasiak; Lukasz Dziki; Michał Mik; Adam Dziki; Czesław S Cierniewski
Journal:  J Biol Chem       Date:  2012-08-16       Impact factor: 5.157

4.  Effective hepatocyte transplantation using rat hepatocytes with low asialoglycoprotein receptor expression.

Authors:  Hirohiko Ise; Toshio Nikaido; Naoki Negishi; Nobuhiro Sugihara; Fumitaka Suzuki; Toshihiro Akaike; Uichi Ikeda
Journal:  Am J Pathol       Date:  2004-08       Impact factor: 4.307

5.  A hybrid substratum for primary hepatocyte culture that enhances hepatic functionality with low serum dependency.

Authors:  Qingyuan Meng; Chunsheng Tao; Zhiye Qiu; Toshihiro Akaike; Fuzhai Cui; Xiumei Wang
Journal:  Int J Nanomedicine       Date:  2015-03-23

Review 6.  Efficient hepatic delivery of drugs: novel strategies and their significance.

Authors:  Nidhi Mishra; Narayan Prasad Yadav; Vineet Kumar Rai; Priyam Sinha; Kuldeep Singh Yadav; Sanyog Jain; Sumit Arora
Journal:  Biomed Res Int       Date:  2013-10-28       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.